Business
Lannett Company, Lanexa Biologics and Sunshine Lake Pharma announce FDA Approval of LANGLARA™ an Interchangeable Biosimilar of Lantus® (insulin glargine)
PHILADELPHIA, May 04, 2026--Lannett Company, Inc., Lanexa Biologics, a wholly owned subsidiary of Lannett, and Sunshine Lake Pharma today announced that the U.S. Food and Drug Administration (FDA) has approved LANGLARA™ (insulin glargine-aldy), as a biosimilar to Lantus® (insulin glargine), for the treatment of adults and pediatric patients with type 1 diabetes mellitus and adults with type 2 diabetes mellitus. The FDA has determined that LANGLARA is interchangeable with the reference drug, enab
About this update from Sunshine Lake Pharma Co., Ltd. Class H
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":360,"url":"https://media.zenfs.com/en/business-wire.com/78faf73007ac45fd9291025c7d4ea6d9"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/FwBtz2X6u4KPUbIMMq3KxQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTcyMA--/https://media.zenfs.com/en/business-wire.com/78faf73007ac45fd9291025c7d4ea6d9","width":480,"height":360}},"lazy":false},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":360,"url":"https://media.zenfs.com/en/business-wire.com/5b22b7e7055afb5989ad8996f7ce0cb8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/tk6oIHJIQhJBPlzWkq.RgQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTcyMA--/https://media.zenfs.com/en/business-wire.com/5b22b7e7055afb5989ad8996f7ce0cb8","width":480,"height":360}}},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":360,"url":"https://media.zenfs.com/en/business-wire.com/5cbd058103aed87a352b10b754763032"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/jQxVOhhXzQyCoAdWT35b7Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTcyMA--/https://media.zenfs.com/en/business-wire.com/5cbd058103aed87a352b10b754763032","width":480,"height":360}}},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1200,"height":314,"url":"https://media.zenfs.com/en/business-wire.com/e252f7eb9589db6fcce3196c66ce6fde"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/__2DeSn0kd6e0TjVKN8j5g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTI1MQ--/https://media.zenfs.com/en/business-wire.com/e252f7eb9589db6fcce3196c66ce6fde","width":960,"height":251},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/uUKr7oqq3lQQs6kf_F9Zqg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD02Mjg-/https://media.zenfs.com/en/business-wire.com/e252f7eb9589db6fcce3196c66ce6fde","width":1200,"height":314}}},{"type":"text","content":"This Interchangeable Biosimilar Insulin Glargine Approved for U.S. Distribution Through Newly Established Subsidiary Lanexa Biologics LLC","length":137,"tagName":"p","attribs":{}},{"type":"te...